All In Biotech

Drug Trial Radar · NCT07420257

A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of CM326 in Participants With Chronic Rhinosinusitis With Nasal Polyposis

Last checked: Nov 19, 2026Latest source record: Feb 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 212 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

212

Planned (sponsor's estimate)

Start

Feb 28, 2026

Primary completion

Oct 30, 2028

Study completion Oct 30, 2028

Sponsor

Sponsor type
Industry
First posted
Feb 19, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-center, randomized, double blind, placebo-controlled Phase III study to evaluate the efficacy and safety of CM326, and to observe the Pharmacokinetics, Pharmacodynamics and I immumogenicity\[c2.1\] of CM326 in patients with chronic rhinosinusitis with nasal polyps (CRSwNP).The study consists of four periods, including an up to 4-week screening/run-in period, a 24-week double-blind randomized treatment period, a 28-week open-label treatment period, and an 8-week safety follow-up period.

Conditions

  • Chronic Rhinosinusitis With Nasal Polyps

Interventions

  • CM326 injectionBiological

    CM326 injection, administered subcutaneously, once every 4 weeks

  • Placebo of CM326Drug

    Placebo of CM326, administered subcutaneously, once every 4 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in Nasal Polyp Score(NPS) at week 24Time frame: 24 weeks
  2. Change of Nasal Congestion Score(NCS) at week 24Time frame: 24 weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.